S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Is Gold Really Boring? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Is Gold Really Boring? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Is Gold Really Boring? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Is Gold Really Boring? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales

MEI Pharma (MEIP) Competitors

$4.18
-0.08 (-1.88%)
(As of 02/27/2024 ET)

MEIP vs. ONCT, APRE, VIRX, DRRX, RGLS, YMTX, LEXX, NRXP, UBX, and TXMD

Should you be buying MEI Pharma stock or one of its competitors? The main competitors of MEI Pharma include Oncternal Therapeutics (ONCT), Aprea Therapeutics (APRE), Viracta Therapeutics (VIRX), DURECT (DRRX), Regulus Therapeutics (RGLS), Yumanity Therapeutics (YMTX), Lexaria Bioscience (LEXX), NRx Pharmaceuticals (NRXP), Unity Biotechnology (UBX), and TherapeuticsMD (TXMD). These companies are all part of the "pharmaceutical preparations" industry.

MEI Pharma vs.

Oncternal Therapeutics (NASDAQ:ONCT) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership, dividends and community ranking.

16.1% of Oncternal Therapeutics shares are owned by institutional investors. Comparatively, 41.9% of MEI Pharma shares are owned by institutional investors. 8.0% of Oncternal Therapeutics shares are owned by insiders. Comparatively, 3.9% of MEI Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MEI Pharma has a net margin of 39.06% compared to MEI Pharma's net margin of -6,330.05%. Oncternal Therapeutics' return on equity of 39.72% beat MEI Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Oncternal Therapeutics-6,330.05% -85.29% -75.54%
MEI Pharma 39.06%39.72%18.26%

MEI Pharma received 343 more outperform votes than Oncternal Therapeutics when rated by MarketBeat users. Likewise, 60.46% of users gave MEI Pharma an outperform vote while only 32.14% of users gave Oncternal Therapeutics an outperform vote.

CompanyUnderperformOutperform
Oncternal TherapeuticsOutperform Votes
27
32.14%
Underperform Votes
57
67.86%
MEI PharmaOutperform Votes
370
60.46%
Underperform Votes
242
39.54%

Oncternal Therapeutics presently has a consensus price target of $69.00, suggesting a potential upside of 614.28%. MEI Pharma has a consensus price target of $7.00, suggesting a potential upside of 67.46%. Given MEI Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Oncternal Therapeutics is more favorable than MEI Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncternal Therapeutics
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
MEI Pharma
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

MEI Pharma has higher revenue and earnings than Oncternal Therapeutics. Oncternal Therapeutics is trading at a lower price-to-earnings ratio than MEI Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncternal Therapeutics$1.49M19.13-$44.17M-$14.40-0.67
MEI Pharma$48.82M0.57-$31.84M$2.971.41

Oncternal Therapeutics has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.

In the previous week, Oncternal Therapeutics had 1 more articles in the media than MEI Pharma. MarketBeat recorded 3 mentions for Oncternal Therapeutics and 2 mentions for MEI Pharma. Oncternal Therapeutics' average media sentiment score of 0.67 beat MEI Pharma's score of 0.00 indicating that MEI Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncternal Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
MEI Pharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

MEI Pharma beats Oncternal Therapeutics on 11 of the 18 factors compared between the two stocks.


Get MEI Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MEIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MEIP vs. The Competition

MetricMEI PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$27.84M$6.44B$5.01B$7.50B
Dividend YieldN/A2.78%2.84%3.87%
P/E Ratio1.4118.43267.0218.55
Price / Sales0.57185.683,368.99160.05
Price / CashN/A18.3325.7525.78
Price / Book1.135.524.704.64
Net Income-$31.84M$112.37M$112.36M$210.98M
7 Day Performance-5.43%6.49%5.35%2.96%
1 Month Performance-8.13%14.01%13.51%5.38%
1 Year Performance-5.94%5.09%13.45%8.21%

MEI Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONCT
Oncternal Therapeutics
1.8849 of 5 stars
$9.66
+4.3%
$69.00
+614.3%
-46.3%$28.50M$1.49M-0.6730
APRE
Aprea Therapeutics
2.6093 of 5 stars
$7.16
+0.1%
$14.50
+102.5%
+41.5%$26.78MN/A-1.799
VIRX
Viracta Therapeutics
2.077 of 5 stars
$0.76
+8.6%
$7.75
+919.7%
-54.5%$29.35MN/A-0.6141Gap Up
DRRX
DURECT
4.0417 of 5 stars
$1.00
+4.2%
$35.00
+3,417.2%
-80.2%$29.68M$19.28M-0.6372Upcoming Earnings
RGLS
Regulus Therapeutics
2.7155 of 5 stars
$1.51
+5.6%
$10.50
+597.7%
+11.5%$30.43MN/A-0.9529Analyst Report
News Coverage
High Trading Volume
YMTX
Yumanity Therapeutics
0 of 5 stars
$2.32
-7.9%
N/A-64.8%$25.19M$4.84M-0.7740Gap Down
LEXX
Lexaria Bioscience
0.3389 of 5 stars
$2.40
+6.2%
$2.00
-16.7%
-20.7%$25.06M$230,000.00-2.865Gap Up
High Trading Volume
NRXP
NRx Pharmaceuticals
0.5104 of 5 stars
$0.29
-30.7%
N/A-70.9%$25.04MN/A-0.582News Coverage
Gap Down
High Trading Volume
UBX
Unity Biotechnology
4.5441 of 5 stars
$1.83
-2.1%
$6.50
+255.2%
-58.5%$30.72M$240,000.00-0.5022Positive News
TXMD
TherapeuticsMD
0.4955 of 5 stars
$2.35
+2.6%
N/A-52.4%$24.86M$69.96M0.001Analyst Report

Related Companies and Tools

This page (NASDAQ:MEIP) was last updated on 2/28/2024 by MarketBeat.com Staff